Lv59
880 积分 2026-07-08 加入
Nonclinical teratogenicity safety assessment of CRBN-engaging targeted protein degraders: Points to consider
22天前
已完结
Advancing New Chemical Modalities into Clinical Studies
1个月前
已完结
Mechanism of hepatobiliary toxicity of the LPA1 antagonist BMS-986020 developed to treat idiopathic pulmonary fibrosis: Contrasts with BMS-986234 and BMS-986278
1个月前
已完结
Discovery of TRPA1 Antagonist GDC-6599: Derisking Preclinical Toxicity and Aldehyde Oxidase Metabolism with a Potential First-in-Class Therapy for Respiratory Disease
2个月前
已完结
New approach methodologies (NAMs) in drug safety assessment: A vision of the future
2个月前
已完结
Application of new approach methodologies for nonclinical safety assessment of drug candidates
2个月前
已完结
皖公网安备34019202002308
